SCS Capital Management LLC Purchases New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• SCS Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals, purchasing 171,077 shares for approximately $46 million, making it the firm's 28th largest position.
• Alnylam Pharmaceuticals recently reported earnings of $0.32 per share, which exceeded analysts' estimates and resulted in year-over-year revenue growth of 17.3%.
• Insider trading activity shows significant sales, with executives selling 57,594 shares totaling around $25.5 million in the last quarter, indicating a 6.71% drop in one executive's ownership.

SCS Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 171,077 shares of the biopharmaceutical company's stock, valued at approximately $46,194,000. Alnylam Pharmaceuticals accounts for approximately 0.6% of SCS Capital Management LLC's portfolio, making the stock its 28th largest position. SCS Capital Management LLC owned 0.13% of Alnylam Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Investment Management Corp of Ontario lifted its position in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock valued at $1,670,000 after acquiring an additional 40 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Alnylam Pharmaceuticals by 10.3% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company's stock worth $142,000 after buying an additional 49 shares during the last quarter. Edmond DE Rothschild Holding S.A. raised its holdings in Alnylam Pharmaceuticals by 18.2% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 49 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Alnylam Pharmaceuticals by 9.2% in the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp raised its holdings in Alnylam Pharmaceuticals by 5.3% in the first quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company's stock worth $274,000 after buying an additional 51 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the transaction, the executive vice president owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dennis A. Ausiello sold 31,448 shares of the business's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director directly owned 911 shares in the company, valued at $397,724.38. This trade represents a 97.18% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 57,594 shares of company stock valued at $25,551,456. Insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $455.03 on Tuesday. The firm has a market cap of $59.65 billion, a P/E ratio of -184.22 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $469.81. The company has a 50 day simple moving average of $390.05 and a two-hundred day simple moving average of $311.54. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company's revenue was up 17.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the subject of several recent analyst reports. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a report on Friday, July 11th. JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. UBS Group lifted their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Finally, HC Wainwright reiterated a "buy" rating and issued a $570.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $417.38.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.